• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Abbott and Boston Scientific get matching downgrades from Morgan Keegan

Abbott and Boston Scientific get matching downgrades from Morgan Keegan

August 26, 2011 By MassDevice staff

Abbott
Boston Scientific

Morgan Keegan analyst Jay Wald handed Abbott (NYSE:ABT) and Boston Scientific Corp. (NYSE:BSX) a set of matching downgrades this week, citing uncertainty about the market.

Wald downgraded both companies to "market perform" from "outperform" and lowered price targets for stocks.

"It appears that investors’ risk assessments are changing in the wake of the S&P downgrade, continued eurozone challenges, and continued weakness in and uncertainty about the U.S. economy," he wrote, adding that neither company offered any "relative upside" to investors any longer.

The downgrades came the day after industry giant Medtronic Inc. (NYSE:MDT) released its quarterly earnings report, which showed declines in sales for its spinal implants and defibrillators. While MDT shares gained 6 percent on new CEO Omar Ishrak’s efficiency mission, Wells Fargo analyst Larry Biegelsen warned that the plans would take time to produce "tangible benefits."

Wald reiterated his grade for Medtronic, which was already at "market perform," the Associated Press reported.

Boston Scientific’s shares this month dipped below $6 for the first time in almost a year. The Natick, Mass.-based medical device colossus has had a roller-coaster stock ride, with two upgrades and one downgrade from analysts in June.

Abbott’s “beat & raise” second quarter earnings report failed to impress Wall Street last month, despite the health care products giant reporting strong second-quarter sales and earnings figures — including a nearly 100 percent top-line surge for its coronary stents business.

The company boosted its diluted EPS guidance for the fully year to between $4.58 and $4.68, up from $4.54 to $4.64, excluding special items. That failed to impress The Street, where ABT shares were down about 1 percent to $52.40 in mid-day trading on July 20.

Filed Under: News Well, Wall Street Beat Tagged With: Abbott, Boston Scientific

More recent news

  • RadNet closes iCAD acquisition, expands AI breast‑imaging portfolio
  • Hyperfine reports first commercial sales of next-gen AI-powered Swoop
  • Stereotaxis announces $12.5M offering
  • Nuwellis ends clinical trial of its ultrafiltration tech for heart failure
  • NanoVibronix enters into $50M financing agreement

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy